HUE031529T2 - Adenozin Al agonisták és karbonsavanhidráz inhibitorok kombinációs készítményei intraokuláris nyomás csökkentésére - Google Patents
Adenozin Al agonisták és karbonsavanhidráz inhibitorok kombinációs készítményei intraokuláris nyomás csökkentésére Download PDFInfo
- Publication number
- HUE031529T2 HUE031529T2 HUE11757063A HUE11757063A HUE031529T2 HU E031529 T2 HUE031529 T2 HU E031529T2 HU E11757063 A HUE11757063 A HU E11757063A HU E11757063 A HUE11757063 A HU E11757063A HU E031529 T2 HUE031529 T2 HU E031529T2
- Authority
- HU
- Hungary
- Prior art keywords
- combination
- eye
- subject
- nitrate
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Claims (7)
- Adérmzm Al agonkiák és katbonsavatdiidráz inhibitorok kombinációs készítményéi Itili^kj^ÉrWy^îEis csökkentésére SzabadaImi igénypontok I < Szemészeti kombináció, mely i)képleî(k{(2Il»3S54Rs5R)-§-(6-(ciklopen{i!ammo)-9Ik|îmin>'9-il)~3,4-diWdroxitetTakklroikrêm-2di)nmtM nitrátot, vagy gyógyászé sóját, és ti) egy iejiarii, brinzokmid vagy aecíazolamid közül választott karbonsavanbldráz inhibitort tmtalmaz* egy alany intraokolárís nyomás csökkentésében tör ténő alkalmazásra.
- 2. Kombináció a/ I. igénypont szerinti tdkalmazÉsm, ahol a knámosavaahidrá^ Inblblíor dorzolamkl
- 3. Kombináció az k és 2, igénypontok bármelyike szeilMi áikalmázlára, #o| a ((2R,3S,4RJR)"5A6~icikiopemtiamloo}-9Ii-pnrim9-"il^3,4-dibiirokitetrabidrefemn-2-iOmeiil nitrátot az alany szeméhez a karkmsavanhkiráz inhibitor adagolásával egyszerre, kik fon-kiilon vagy egymást követően adjuk.
- 4, Kombináció az. 1-3, igénypontok bármelyike szerimi alkalmazásra·, ahol körűiéiül 0.05 mg/mi és körülbelül 7,0 mg/ml {t 2R..1 S,4R.5R)-5-(ó~iciklofxmtilinnino)-9H-piirin-'O'-i 1 )-3,4-dihidroxiteimhidrofuran~2-ü)metil nitrátot adtaik körülbelül 2% karbonmymÉIdráz inhibit» rál M ákipy szeméhez naponta !-4 alkalommák
- 5, Kombináció a 4, igénypont .szerinti alkalmazásra, ahol körülbelül 20-700 pg* vagy 20-350 μ g {(2R,3S,4RJR)-S-(6-{cikiopenülamino}-9i1“puríioO~il)~3.4~óíhidrosjteírahidroiuran-2-Ilimet il nitrátot adónk az alany szeméhez naponta 1-2 alkalommal,
- 6, Kombtíiáoíö iaz Ι -S. igénypontok bármelyike szerinti alkalmazásra, áhol 4 5-{6~(eik.lopeftiÍIammo)~9H-porín~9~íl)~3ékdihidroxitetmbíÉ’Oforan-2-il>mctii nitrátot és a karbonsavánhidráz inhibitort topikálísan, egy vagy több szemeseidként adagoljuk az alany szeméhez,
- 7, Kombináció az 1 -6. igénypontok bármelyike szerinti alkalmazásra, egy alany szemében megnövekedést intraokuíáás nyomás által okozott betegsá|ok és állapotok kezelésében történd aiknlmáZásre^ áhól az emberben a megnövekedfött Idtraókulárís nyomás által okozott betegség és állapot okuláxis magas yémyömis Is primer nyílt zúgó glaukóma. $, Kik mely az 1-7. igénypontok bármelyike szerinti kombinációt tarMltnazzá, egy alany szemében megnövekedett intraokuláris nyomás csökkemésélsen törtépö alkatoazásót, li KomMbiemj mely 1} ((2E,3S.4Ié,5R}-5''{6-{cikÍopeötilamino}~91í-purin''9-il)-3,4-· dihidroxitetrahidrofuran-2-iI )me tiI nitrátot vagy gyógyászattiag elfogadható séfát és ii) egy dorzolamid, bánzolamid vagy aeetazolamid közül választott karbensavanhidráz inhibitort tartalmaz, gyógyszerem Älnö alkalmazásra.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31572110P | 2010-03-19 | 2010-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE031529T2 true HUE031529T2 (hu) | 2017-07-28 |
Family
ID=44649619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11757063A HUE031529T2 (hu) | 2010-03-19 | 2011-03-18 | Adenozin Al agonisták és karbonsavanhidráz inhibitorok kombinációs készítményei intraokuláris nyomás csökkentésére |
Country Status (17)
Country | Link |
---|---|
US (1) | US8440639B2 (hu) |
EP (1) | EP2555775B1 (hu) |
JP (1) | JP2013522322A (hu) |
CN (1) | CN102933220A (hu) |
CY (1) | CY1118495T1 (hu) |
DK (1) | DK2555775T3 (hu) |
ES (1) | ES2613254T3 (hu) |
HR (1) | HRP20170008T1 (hu) |
HU (1) | HUE031529T2 (hu) |
LT (1) | LT2555775T (hu) |
ME (1) | ME02593B (hu) |
PL (1) | PL2555775T3 (hu) |
PT (1) | PT2555775T (hu) |
RS (1) | RS55617B1 (hu) |
SI (1) | SI2555775T1 (hu) |
SM (1) | SMT201700019B (hu) |
WO (1) | WO2011116290A1 (hu) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2762064A1 (en) * | 2009-05-01 | 2010-11-04 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans |
JP2013516495A (ja) * | 2010-01-11 | 2013-05-13 | イノテック ファーマシューティカルズ コーポレイション | 眼圧を低下させる組合せ、キット、および方法 |
JP2013523739A (ja) * | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
BR112014018413A8 (pt) * | 2012-01-26 | 2017-07-11 | Inotek Pharmaceuticals Corp | Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo |
CN105188714A (zh) | 2013-03-15 | 2015-12-23 | 伊诺泰克制药公司 | 眼用配制品 |
CN107406479A (zh) * | 2014-12-03 | 2017-11-28 | 伊诺泰克制药公司 | 预防、减轻或治疗黄斑变性的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101010085B (zh) | 2004-05-26 | 2012-12-26 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
DE602005020286D1 (de) | 2004-05-26 | 2010-05-12 | Inotek Pharmaceuticals Corp | Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür |
WO2007064795A2 (en) * | 2005-11-30 | 2007-06-07 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
CA2762064A1 (en) * | 2009-05-01 | 2010-11-04 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans |
-
2011
- 2011-03-18 PL PL11757063T patent/PL2555775T3/pl unknown
- 2011-03-18 JP JP2013500232A patent/JP2013522322A/ja active Pending
- 2011-03-18 EP EP11757063.0A patent/EP2555775B1/en active Active
- 2011-03-18 CN CN2011800147015A patent/CN102933220A/zh active Pending
- 2011-03-18 HU HUE11757063A patent/HUE031529T2/hu unknown
- 2011-03-18 US US13/051,633 patent/US8440639B2/en not_active Expired - Fee Related
- 2011-03-18 RS RS20170065A patent/RS55617B1/sr unknown
- 2011-03-18 ES ES11757063.0T patent/ES2613254T3/es active Active
- 2011-03-18 SI SI201131085A patent/SI2555775T1/sl unknown
- 2011-03-18 ME MEP-2017-12A patent/ME02593B/me unknown
- 2011-03-18 PT PT117570630T patent/PT2555775T/pt unknown
- 2011-03-18 LT LTEP11757063.0T patent/LT2555775T/lt unknown
- 2011-03-18 DK DK11757063.0T patent/DK2555775T3/en active
- 2011-03-18 WO PCT/US2011/029010 patent/WO2011116290A1/en active Application Filing
-
2017
- 2017-01-04 HR HRP20170008TT patent/HRP20170008T1/hr unknown
- 2017-01-16 SM SM201700019T patent/SMT201700019B/it unknown
- 2017-01-25 CY CY20171100110T patent/CY1118495T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ME02593B (me) | 2017-06-20 |
PL2555775T3 (pl) | 2017-08-31 |
US20110245193A1 (en) | 2011-10-06 |
EP2555775B1 (en) | 2016-12-07 |
SMT201700019B (it) | 2017-03-08 |
WO2011116290A1 (en) | 2011-09-22 |
HRP20170008T1 (hr) | 2017-03-10 |
SI2555775T1 (sl) | 2017-05-31 |
CN102933220A (zh) | 2013-02-13 |
US8440639B2 (en) | 2013-05-14 |
PT2555775T (pt) | 2017-02-01 |
LT2555775T (lt) | 2017-04-25 |
DK2555775T3 (en) | 2017-02-06 |
EP2555775A1 (en) | 2013-02-13 |
ES2613254T3 (es) | 2017-05-23 |
CY1118495T1 (el) | 2017-07-12 |
JP2013522322A (ja) | 2013-06-13 |
EP2555775A4 (en) | 2013-08-28 |
RS55617B1 (sr) | 2017-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010242943B2 (en) | Method of reducing intraocular pressure in humans | |
EP2555776B1 (en) | Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure | |
US9370530B2 (en) | Combination, kit and method of reducing intraocular pressure | |
DK2555775T3 (en) | Combination Compositions of Adenosine A1 Agonists and Carbonic Anhydrase Inhibitors to Reduce Intraocular Pressure |